Developments Milestone Pharma enrolls first patient in Phase 3 etripamil trial Milestone Pharmaceuticals (NASDAQ:MIST) enrolled the first patient in its Phase 3 RAPID trial evaluating etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT). PSVT is characterized by... November 18, 2020